Rifaximin and the DCA–serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?

Journal of Hepatology 2026

View at publisher

Authors: Chetan Ramesh Kalal, Piyush Gupta

DOI: 10.1016/j.jhep.2026.06.018

Cited by: 1

References: 4

Fields of Study & Subjects

Liver Disease and Transplantation Liver Diseases and Immunity Drug Transport and Resistance Mechanisms

References 4